Skye Bioscience, Inc. (SKYE)
1.86
+0.08
(+4.49%)
USD |
NASDAQ |
Sep 04, 16:00
1.86
0.00 (0.00%)
After-Hours: 20:00
Skye Bioscience Cash from Investing (Quarterly) : 7.142M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.142M |
| March 31, 2026 | 10.90M |
| December 31, 2025 | -2.804M |
| September 30, 2025 | 7.967M |
| June 30, 2025 | -11.86M |
| March 31, 2025 | -12.81M |
| December 31, 2024 | 0.0904M |
| September 30, 2024 | -1.446M |
| June 30, 2024 | -0.0325M |
| March 31, 2024 | 1.142M |
| December 31, 2023 | -0.007M |
| September 30, 2023 | 1.073M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 5.530M |
| December 31, 2022 | 5.666M |
| September 30, 2022 | -0.3661M |
| June 30, 2022 | -0.084M |
| March 31, 2022 | -0.002M |
| December 31, 2021 | -0.054M |
| September 30, 2021 | -0.0267M |
| June 30, 2021 | 0.0005M |
| March 31, 2021 | -0.0107M |
| December 31, 2020 | -0.0072M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | -0.0033M |
| March 31, 2018 | -0.0011M |
| December 31, 2017 | -0.0197M |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | -0.0111M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | -0.002M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -0.0109M |
| September 30, 2014 | -0.0124M |
| April 30, 2014 | 0.00 |
| January 31, 2014 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| Viking Therapeutics, Inc. | 109.43M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.122M |
| Cash from Financing (Quarterly) | -0.101M |
| Free Cash Flow | -38.81M |
| Free Cash Flow Per Share (Quarterly) | -1.435 |
| Free Cash Flow to Equity (Quarterly) | -6.989M |
| Free Cash Flow to Firm (Quarterly) | -7.118M |
| Free Cash Flow Yield | -420.7% |